Mesna-Cell Stadapharm (Mesna)

Mesna works by supplying sulfhydryl groups that bind to acrolein, a toxic by‑product generated when cyclophosphamide or ifosfamide is metabolized. This binding forms a non‑reactive complex that is eliminated in the urine, preventing acrolein from damaging the urothelium and thus reducing the incidence of hemorrhagic cystitis.

The dose of Mesna-Cell is determined by the prescribing clinician based on the specific chemotherapy regimen, patient weight, renal function, and treatment protocol. Dosing schedules are individualized and should follow the guidance of the treating oncologist or pharmacist.

Safety data for Mesna-Cell in pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers should evaluate the risk‑benefit ratio before prescribing to pregnant or nursing patients.

To order Mesna-Cell, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including cold‑chain handling if needed) and assistance with import documentation.

Mesna is the standard uroprotective agent for preventing acrolein‑induced bladder toxicity from cyclophosphamide and ifosfamide. Alternatives such as amifostine are less specific for acrolein detoxification and are not routinely used for this indication. Consequently, Mesna remains the preferred choice for protecting the urinary tract during these chemotherapy regimens.

Mesna-Cell should be stored at 2‑8 °C (refrigerated). Keep the product in its original container, protect it from light, and avoid freezing or shaking. If the solution reaches room temperature for a short period, it may be used, but it should be returned to refrigerated conditions promptly.

Mesna-Cell is given by intravenous infusion, typically administered shortly before, during, and after the cyclophosphamide or ifosfamide infusion according to the prescribed schedule. The exact timing and infusion rate are determined by the treating physician and should follow institutional protocols for chemotherapy support.

The most serious risks include severe allergic reactions such as anaphylaxis, marked hypotension that can lead to syncope, pulmonary edema, and rare severe skin disorders like Stevens‑Johnson syndrome. Patients should be monitored closely for any signs of these reactions, and treatment should be discontinued immediately if they occur.

Mesna-Cell should not be used in individuals with a known hypersensitivity to mesna or any of its excipients. Caution is also advised for patients with severe renal impairment, as reduced clearance may diminish its protective effect. In such cases, alternative strategies or dose adjustments should be considered by the healthcare provider.